SBP GROUP (01177): Innovent Biologics Reveals Latest Research Data on Two ADC Candidates at AACR 2026

SBP GROUP (01177) announced that its wholly-owned subsidiary, Innovent Biologics (Shanghai) Co., Ltd., presented the latest research data for two internally developed next-generation antibody-drug conjugates (ADCs)—LM-364, a Nectin-4TME ADC, and LM-338, an STn ADC—at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

LM-364 is a novel Nectin-4TME ADC developed using Innovent’s proprietary tumor microenvironment (TME) platform. The molecule employs an adenine nucleotide (ANP)-dependent binding mechanism. Because ANP concentrations in the tumor microenvironment (at the micromolar level) are significantly higher than in normal tissues (at the nanomolar level), LM-364 achieves conditional high-affinity activation at the tumor site. This enhances drug internalization and toxin release while substantially reducing off-target toxicity in healthy tissues, offering a new approach to addressing long-standing safety challenges in ADC development. Nectin-4 is a clinically validated target that is highly expressed in various solid tumors, including urothelial carcinoma and triple-negative breast cancer. However, its low-level expression in normal tissues has historically led to dose-limiting toxicities such as skin rash and neurotoxicity, posing a major bottleneck in clinical development. LM-364 has already submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), with plans to initiate first-in-human (FIH) clinical trials in 2026.

LM-338 is a potential first-in-class ADC targeting the highly tumor-specific carbohydrate antigen Sialyl-Thomsen-nouveau (STn). It consists of a humanized monoclonal antibody conjugated via a cleavable linker to a topoisomerase I inhibitor, with a drug-to-antibody ratio (DAR) of 4. STn is a truncated O-glycan antigen that is nearly absent in most normal tissues but is highly expressed across a range of solid tumors, including ovarian, breast, bladder, cervical, colorectal, pancreatic, and non-small cell lung cancers. It is regarded as a highly promising target for ADC therapies.